Display Settings:

Format

Send to:

Choose Destination

See 1 citation found by title matching your search:

See comment in PubMed Commons below
Addiction. 2011 Mar;106(3):574-80. doi: 10.1111/j.1360-0443.2010.03170.x. Epub 2010 Oct 6.

Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Author information

  • 1Department of Pharmacology and Experimental Therapeutics Pediatrics, Jefferson Medical College, Philadelphia, PA, USA. walter.kraft@jefferson.edu

Abstract

AIMS:

More than half of infants exposed to opioids in utero develop neonatal abstinence syndrome (NAS) of severity to require pharmacological therapy. Current treatments are associated with prolonged hospitalization. We sought to optimize the dose of sublingual buprenorphine in the treatment of NAS.

DESIGN:

Randomized, Phase 1, open-label, active-control clinical trial comparing sublingual buprenorphine to oral morphine.

SETTING:

Large, urban, tertiary care hospital.

PARTICIPANTS:

Twenty-four term infants requiring pharmacological treatment for NAS.

MEASUREMENTS:

Outcomes were neonatal safety, length of treatment and length of hospitalization.

FINDINGS:

Sublingual buprenorphine was safe and effective. Infants treated with buprenorphine had a 23-day length of treatment compared to 38 days for those treated with morphine (P = 0.01), representing a 40% reduction. Length of hospital stay in the buprenorphine group was reduced 24%, from 42 to 32 days (P = 0.05).

CONCLUSIONS:

Sublingual buprenorphine was safe in NAS, with a substantial efficacy advantage over standard of care therapy with oral morphine.

© 2010 The Authors, Addiction © 2010 Society for the Study of Addiction.

Comment in

PMID:
20925688
[PubMed - indexed for MEDLINE]
PMCID:
PMC3022999
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk